- Health and Wellness
- Innovation and Research
Today, the University of Pittsburgh announced a new partnership with BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company founded to develop medicines for patients with genetic diseases and cancers with clear genetic drivers. It’s one of three such BridgeBio academic collaborations to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
“We are very excited to grow our partnership with BridgeBio,” said Rob A. Rutenbar, senior vice chancellor for research at Pitt. “Bringing together Pitt’s leading medical research enterprise with the drug development expertise of BridgeBio serves our common goal of developing life-saving therapies for those patients most in need.”
Pitt will collaborate with BridgeBio to identify and support the development of novel therapies for patients withgenetic diseases and cancers with clear genetic drivers.
“The chance to partner with exceptional researchers at the Medical University of South Carolina, Stanford University and University of Pittsburgh is a privilege, and we believe will help us advance our mission to discover, create, test and deliver life-changing medicines for patients in need as rapidly as possible,” said BridgeBio founder and CEO Neil Kumar.
BridgeBio, founded in 2015, has a pipeline of more than 30 development programs ranging from early science to advanced clinical trials. Its team of drug discoverers, developers and innovators is committed to applying advances in genetic medicine to help patients as quickly and safely as possible.